The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Preliminary Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Added to Mood Stabilizers for Treatment-Resistant Bipolar Depression
Abstract
OBJECTIVE: Previous studies suggest that the dopamine agonist pramipexole may possess antidepressant properties. The authors conducted a preliminary randomized, placebo-controlled trial to determine the safety and antidepressant efficacy of pramipexole in treatment-resistant bipolar depression. METHOD: Twenty-two depressed outpatients with DSM-IV nonpsychotic bipolar disorder were randomly assigned to receive placebo or flexibly dosed pramipexole (mean maximum dose=1.7 mg/day, SD=1.3) added to existing mood stabilizers for 6 weeks. The primary outcome measure was response, defined as improvement in Hamilton Depression Rating Scale score of 50% or more over the baseline score; secondary analyses involved changes in Clinical Global Impression (CGI) severity scores. RESULTS: More patients given pramipexole (10 [83%] of 12) than patients given placebo (six [60%] of 10) completed the study. Eight (67%) of 12 patients taking pramipexole and two (20%) of 10 taking placebo had an improvement of at least 50% in their Hamilton depression scale scores. The mean percentage of improvement from baseline Hamilton depression scale scores was greater for patients taking pramipexole (48%) than for those taking placebo (21%). Mean improvements in CGI severity were also greater with pramipexole than placebo. No patients discontinued the study because of adverse events except for one patient who became hypomanic while taking pramipexole. CONCLUSIONS: Pramipexole was a safe and effective antidepressant among patients with bipolar depression. Larger randomized, controlled trials are needed to affirm these initial observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“Depressive and manic symptoms were rated by using the 17- item Hamilton Depression Rating Scale (10) and the Young Mania Rating Scale (11) after achieving adequate interrater reliability.”
MethodA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 5×
“Depressive and manic symptoms were rated by using the 17- item Hamilton Depression Rating Scale (10) and the Young Mania Rating Scale (11) after achieving adequate interrater reliability.”
MethodInfluentialNemeroff, C. B., Evans, D. L., Gyulai, L., Sachs, G. S., Bowden, C. L., Gergel, I. P., Oakes, R., & Pitts, C. D. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.906 · Cited by 407
Tranylcypromine versus imipramine in anergic bipolar depression
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.7.910 · Cited by 360
Young, L. T., Joffe, R. T., Robb, J. C., MacQueen, G. M., Marriott, M., & Patelis-Siotis, I. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.124 · Cited by 211
Sporn, J., Ghaemi, S. N., Sambur, M. R., Rankin, M. A., Recht, J., Sachs, G. S., Rosenbaum, J. F., & D, M. F. M. (2000) · Annals of Clinical Psychiatry · doi:10.1023/a:1009060800999 · Cited by 153
Pramipexole in treatment‐resistant depression: a 16‐week naturalistic study
Lattanzi, L., Dell’Osso, L., Cassano, P., Pini, S., Rucci, P., Houck, P. R., Gemignani, A., Battistini, G., Bassi, A., Abelli, M., et al. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01171.x · Cited by 150
Post, R. M., Altshuler, L. L., Frye, M. A., Suppes, T. M., Rush, A. J., Keck, P. E., McElroy, S. L., Denicoff, K. D., Leverich, G. S., Kupka, R., et al. (2001) · Bipolar Disorders · doi:10.1034/j.1399-5618.2001.030505.x · Cited by 139
Pramipexole in Refractory Bipolar Depression
Goldberg, J. F., Frye, M. A., & Dunn, R. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.798 · Cited by 46
Self-citationPallis, E. G., Thermos, K., & Spyraki, C. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01698.x · Cited by 45
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244
Pathophysiology of depression: do we have any solid evidence of interest to clinicians?
HASLER, G. (2010) · World Psychiatry · doi:10.1002/j.2051-5545.2010.tb00298.x · Cited by 604
Ashok, A. H., Marques, T. R., Jauhar, S., Nour, M. M., Goodwin, G. M., Young, A. H., & Howes, O. D. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.16 · Cited by 546
(2007) · PubMed · Cited by 453
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“One study with a mixed Bipolar I and II population (Goldberg et al. 2004) and one pilot study in Bipolar II patients also confi rmed effi cacy of pramipexole add-on to lithium or valproate in Bipolar II depression (Zarate et al. 2004)(CE B, RG 3).”
ResultDopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder
Berk, M., Dodd, S., Kauer‐Sant’Anna, M., Malhi, G. S., Bourin, M., Kapczinski, F., & Norman, T. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01058.x · Cited by 396
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Bupropion: pharmacology and therapeutic applications
Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1249 · Cited by 352
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study
Zarate, C. A., Payne, J. L., Singh, J., Quiroz, J. A., Luckenbaugh, D. A., Denicoff, K. D., Charney, D. S., & Manji, H. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.013 · Cited by 347
Suppes, T., Dennehy, E. B., Hirschfeld, R. M. A., Altshuler, L. L., Bowden, C. L., Calabrese, J. R., Crismon, M. L., Ketter, T. A., Sachs, G. S., Swann, A. C., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0710 · Cited by 330
Dopamine, depression and antidepressants
Dailly, E., Chenu, F., Renard, C. E., & Bourin, M. (2004) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00287.x · Cited by 302
Guiard, B. P., El Mansari, M., Merali, Z., & Blier, P. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008383 · Cited by 302
The burden of severe depression: A review of diagnostic challenges and treatment alternatives
Nemeroff, C. B. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.008 · Cited by 295
The role of dopamine in bipolar disorder
Cousins, D. A., Butts, K., & Young, A. H. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00760.x · Cited by 291
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.105 · Cited by 271
Compulsive eating and weight gain related to dopamine agonist use
Nirenberg, M. J., & Waters, C. (2006) · Movement Disorders · doi:10.1002/mds.20757 · Cited by 262
Liu, Y., Zhao, J., & Guo, W. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.02201 · Cited by 261
Nierenberg, A. A., Ostacher, M. J., Calabrese, J. R., Ketter, T. A., Marangell, L. B., Miklowitz, D. J., Miyahara, S., Bauer, M. S., Thase, M. E., Wisniewski, S. R., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.210 · Cited by 257
Diminished effort on a progressive ratio task in both unipolar and bipolar depression
Hershenberg, R., Satterthwaite, T. D., Daldal, A., Katchmar, N., Moore, T. M., Kable, J. W., & Wolf, D. H. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.003 · Cited by 157
“Given mixed evidence for antidepressant use in bipolar disorder, including those enhancing dopaminergic function (Bond et al., 2012; Goldberg et al., 2004; Pacchiarotti et al., 2013), objective measures of amotivation could help tailor individualized risk-benefit calculations for using dopaminergic…”
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Berk, M., & Dodd, S. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2004.00152.x · Cited by 134
Mapping inflammation onto mood: inflammatory mediators of anhedonia
Swardfager, W., Rosenblat, J. D., Benlamri, M., & McIntyre, R. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.017 · Cited by 125
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
Bipolar depression: issues in diagnosis and treatment
Thase, M. E. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220500326425 · Cited by 89
Ropinirole in treatment-resistant depression: a 16-week pilot study
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000612 · Cited by 73
Hori, H., & Kunugi, H. (2012) · The Scientific World Journal · doi:10.1100/2012/372474 · Cited by 62
Atypical antipsychotics in bipolar depression: Neurobiological basis and clinical implications
Brugue, E., & Vieta, E. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.014 · Cited by 54
Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis
Szmulewicz, A. G., Angriman, F., Samamé, C., Ferraris, A., Vigo, D., & Strejilevich, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12712 · Cited by 37
Current landscape, unmet needs, and future directions for treatment of bipolar depression
Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70005-9 · Cited by 36
Pramipexole for stage 2 treatment-resistant major depression: An open study
Inoue, T., Kitaichi, Y., Masui, T., Nakagawa, S., Boku, S., Tanaka, T., Suzuki, K., Nakato, Y., Usui, R., & Koyama, T. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.035 · Cited by 34
Treatment of behavioural symptoms and dementia in Parkinson's disease
Hanagasi, H. A., & Emre, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2005.00317.x · Cited by 24
Metadata
- Authors
- Goldberg, J. F., Burdick, K. E., & Endick, C. J.
- Venue
- American Journal of Psychiatry
- Published
- 2004-03-01
- Volume
- 161
- Issue
- 3
- Pages
- 564-566
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2147099798
- Cited by
- 372
- References
- 11
- FWCI
- 18.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.